Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Inari focuses on ailments like venous thromboembolism, or blood clots in a patient's veins, providing surgical products to treat the issues. Inari Shares Rose 30% Monday, Over 20% Tuesday Morning The ...

Inari’s catalog includes the catheter-based FlowTriever and ClotTriever systems for mechanically removing blood clots in cases of pulmonary embolism and deep vein thrombosis, respectively.

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.

As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty ...

Inari Medical Inc (NASDAQ:NARI) makes medical devices to treat blot clots in veins and their main products are designed to remove clots from deep veins and pulmonary arteries without using clot ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Inari shareholders are getting a fair price relative ... risks and costs of thrombolytic therapy (drugs meant to break up clots) and a growing database on the safety and efficacy of mechanical ...

Inari focuses on ailments like venous thromboembolism, or blood clots in a patient's veins, providing surgical products to treat the issues. Inari Shares Rose 30% Monday, Over 20% Tuesday Morning ...